• Dabigatran Etexilate: Oral Direct Thrombin Inhibition

  2026-10-03

  The 2011 clinical review by Blommel and Blommel presents dabigatran etexilate as a major pharmacologic advance: an orally administered prodrug that produces direct, reversible thrombin inhibition without the routine anticoagulation monitoring associated with vitamin K antagonists. Its practical significance lies in predictable pharmacology and broad clinical investigation, balanced against bleeding risk, gastrointestinal adverse effects, and dependence on renal function.

• Poly(A) Tailing as a Translational Lever

  2026-10-02

  A mechanistic and strategic guide to using enzymatic poly(A) tailing to improve RNA workflow control, interpret mitochondrial biology, and strengthen translational validation.

• Pregnenolone Carbonitrile: PXR Workflows

  2026-10-01

  Pregnenolone Carbonitrile is a practical rodent PXR agonist for connecting CYP3A regulation, xenobiotic clearance, and liver injury biology. Its utility extends from controlled cell assays to microbiota-aware sepsis and fibrosis workflows, provided species, solubility, and exposure variables are tightly managed.

• TMB in P. vivax Serology: Signal to Decision

  2026-10-01

  TMB, or 3,3′,5,5′-Tetramethylbenzidine, converts HRP-linked epitope recognition into a measurable color signal. This article explains how to design TMB-based P. vivax serology around analytical controls, asymptomatic-infection interpretation, and the practical limits of translating promising epitopes into surveillance assays.

• RP3-340N1.2, IL-6, and NSCLC Progression

  2026-09-30

  This reference study identifies the lncRNA RP3-340N1.2 as a post-transcriptional regulator of IL-6 mRNA stability in non-small cell lung cancer. Its combination of RNA sequencing, genetic perturbation, mRNA decay analysis, RNA immunoprecipitation, and macrophage co-culture links an RNA-binding protein mechanism to tumor-cell and microenvironmental phenotypes.

• Allosteric PDK4 Inhibitors for Metabolic Disease

  2026-09-30

  Jeon and colleagues identified anthraquinone-derived allosteric inhibitors of pyruvate dehydrogenase kinase 4, with compound 8c showing nanomolar biochemical potency and activity across metabolic, allergic, and cancer-related models. The study combines medicinal chemistry, pharmacokinetic assessment, molecular docking, and disease-relevant experiments to support a new scaffold for PDK4 inhibitor development.

• Ouabain in EDH Vascular Mechanism Studies

  2026-09-29

  Explore how Ouabain, a selective Na+/K+-ATPase inhibitor, can serve as a causal perturbation tool in endothelium-dependent hyperpolarization studies. This article translates recent vascular findings into rigorous assay-design decisions for cardiovascular research without confusing pump inhibition with nonspecific toxicity.

• Kozak Libraries Link Transgene Levels to Cell Function

  2026-09-29

  Shukla and colleagues developed a pooled Kozak-sequence library that calibrates translation-initiation variants against transgene abundance in a shared genomic context. The approach enables researchers to separate effects caused by protein sequence from effects caused by expression level, with applications demonstrated using ACE2 and STIM1.

• GSTA1 Amplifies α-Amanitin Liver Toxicity

  2026-09-28

  A 2026 study identifies GSTA1 as an unexpected driver of α-amanitin hepatotoxicity rather than a purely protective antioxidant enzyme. By combining mouse toxicology, multi-omics, target-interaction assays, and genetic silencing, the work links GSTA1 upregulation to glutathione depletion, reactive oxygen species accumulation, and hepatocyte injury.

• Resazurin Cell Viability Assay Kit in Bone Research

  2026-09-28

  Use a sensitive, non-toxic cell viability assay to check whether experimental effects in osteoblast studies reflect altered cell health or a pathway-specific response. This practical guide pairs resazurin readouts with the findings of a sclerosteosis study and offers clearly labeled starting conditions for assay optimization.

• Moxifloxacin: From Gyrase Inhibition to Cell Phenotype

  2026-09-27

  Moxifloxacin is a fluoroquinolone antibiotic whose bacterial target biology and host-cell effects answer different research questions. This article connects gyrase mechanism to assay interpretation, highlighting what a structural study of another topoisomerase inhibitor can—and cannot—tell you about moxifloxacin experiments.

• Tetraethylammonium Chloride: Reading K+ Blockade

  2026-09-26

  Tetraethylammonium chloride (TEAC) is a useful potassium-channel perturbation, but its strongest value comes from interpreting what a block does—and does not—prove. This article connects pore-blocking experiments with a landmark β-cell study to help researchers distinguish channel effects from receptor pharmacology.

• CNQX for Circuit Pharmacology and Assay Design

  2026-09-25

  Use CNQX to test whether AMPA/kainate signaling contributes to a response, while preserving NMDA-receptor activity as a separate experimental question. A cardiovascular circuit study illustrates both the value of this selectivity and why a negative CNQX result needs controls before it is interpreted.

• CNQX and the Logic of Negative Circuit Results

  2026-09-25

  CNQX is a selective AMPA/kainate receptor antagonist, but a negative result can be as informative as a positive one when target engagement and circuit location are considered. Learn how a neurocardiovascular study illustrates stronger assay interpretation and more precise glutamatergic experiments.

• 25-Hydroxycholesterol Reprograms Tumor Macrophages

  2026-09-24

  Xiao et al. identify CH25H-derived 25-hydroxycholesterol as an immunometabolic signal that activates lysosomal AMPKα and reinforces STAT6-dependent immunosuppressive macrophage function. The findings connect oxysterol handling to tumor immune status and suggest that targeting CH25H may improve antitumor responses, including in combination with anti-PD-1 therapy.

8169 records 1/545 page Next 12345 下5页 Last page